Scientists Make Spine-Tingling Advance In Medical Science in 2026

Northwestern University scientists have developed the most advanced organoid model for human spinal cord injury to date, using lab-grown tissue to test a promising therapy that targets the damaged spinal cord. The research team used human spinal cord organoids — miniature organs derived from stem cells — to replicate the effects of traumatic injuries.

Scientists Slice Mini Spinal Cords For Science

For the first time, scientists demonstrated that these organoids can mimic key responses to spinal cord damage, including cell death, inflammation, and glial scarring. That scar tissue creates a physical barrier that blocks nerve regeneration after trauma. Published Feb. 11 in the journal Nature Biomedical Engineering, the study represents a major step toward finding treatments for paralyzing injuries.

The organoids, grown over several months from induced pluripotent stem cells, developed complex features including neurons and astrocytes. The team also added microglia — immune cells typically found in the central nervous system — to simulate the inflammatory response that follows spinal cord injury.

Human Tissue Tested For Spinal Injury Therapy

“One of the most exciting aspects of organoids is that we can use them to test new therapies in human tissue,” said Samuel I. Stupp, the study’s senior author and inventor of the therapy. “Short of a clinical trial, it’s the only way you can achieve this objective.”

Stupp serves as the Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine, and Biomedical Engineering at Northwestern, with appointments across multiple schools. He also directs the Center for Regenerative Nanomedicine. Nozomu Takata, a research assistant professor of medicine at Feinberg School of Medicine and a member of the center, is the paper’s first author.

Lab-Grown Spinal Cords Get Horrific Injuries

To model spinal cord injuries, the researchers induced two common types of damage. They cut some organoids with a scalpel to simulate a laceration, similar to a surgical wound. For others, they applied a compressive contusion injury to mimic wounds from car accidents or steep falls. Both injuries caused cells to die and glial scars to form — just as they would in an actual spinal cord injury.

“We could distinguish between the astrocytes that are a part of normal tissue and the astrocytes in the glial scar, which are large and very densely packed,” Stupp said. “We also detected the production of chondroitin sulfate proteoglycans, which are molecules in the nervous system that respond to injury and disease.”

Dancing Their Way To A Spinal Cord Cure

After establishing the injury models, the team tested a regenerative therapy first introduced in 2021. Known as “dancing molecules,” the treatment harnesses molecular motion to repair tissues after traumatic spinal cord injuries. Injected as a liquid, it gels into a network of nanofibers that mimic the extracellular matrix of the spinal cord.

By fine-tuning the collective motion of molecules within the nanofibers, the therapy connects more effectively with constantly moving cellular receptors. When applied to injured organoids, the treatment produced striking results. Inflammation calmed, glial scarring diminished significantly, and neurites — the long extensions that connect neurons — began to grow in organized patterns. Axons, a type of neurite often severed during spinal cord injury, showed regeneration that could potentially reestablish communication networks disrupted by paralysis.

Molecular Motion Key To Spinal Cord Repair

Testing the therapy on healthy organoids confirmed the importance of molecular motion. “The dancing molecules spun out all these long neurites on the surface of the organoid,” Stupp said. “But when we used molecules that had less or no motion, we saw nothing. This difference was very vivid.”

The therapy recently earned Orphan Drug Designation from the U.S. Food and Drug Administration, offering hope that it could improve outcomes for patients with spinal cord injuries. Previous animal studies showed that a one-time injection helped paralyzed mice regain the ability to walk within four weeks.

A New Era Begins For Spinal Injury Research

The organoid model itself represents a significant technical advance. Measuring several millimeters in diameter, these mini spinal cord structures proved large and mature enough to develop realistic injury responses. Compared to testing treatments in animals and humans, organoid research is faster and less expensive while still providing relevant data about human tissue.

Looking ahead, Stupp’s team plans to build even more advanced organoids to model older, chronic injuries that typically feature more stubborn scar tissue. They also envision using the technology for personalized medicine — creating implantable tissue from a patient’s own stem cells to avoid immune rejection after spinal cord trauma. The study received support from the Center for Regenerative Nanomedicine at Northwestern University and a gift from the John Potocsnak Family for spinal cord injury research.